|
Variables
|
Strategic treatment (n=17)
|
mismatched (n=17)
|
p-value
|
|---|
|
Month 6
|
|
⊿TJC (M6-BL)
|
− 6 (− 8, − 4.5)
|
− 5 (− 11, − 2.5)
|
0.9172
|
|
⊿SJC (M6-BL)
|
− 4 (− 7, − 2)
|
− 4 (− 10.5, − 2)
|
0.8086
|
|
⊿DAPSA (M6-BL)
|
− 18.6 (− 27.3, − 13.7)
|
− 18.4 (− 32.4, − 13.3)
|
0.9314
|
|
% decrease, SDAI
|
− 77.7 (− 89.9, − 71.4)
|
− 74.0 (− 82.3, − 53.2
|
0.1432
|
|
Proportion of REM, n (%)
|
7 (41.1)
|
3 (17.6)
|
0.2587
|
|
Proportion of REM/LDA, n (%)
|
17 (100)
|
14 (82.3)
|
0.1136
|
|
Minimal Disease Activity
|
12 (70.6)
|
4 (25.3)
|
0.0075*
|
|
% improvement, PASI
|
86.0 (53.1, 100)
|
100 (17.6, 100)
|
0.9809
|
|
PASI90, n (%)
|
7/15 (46.7)
|
9/14 (64.2)
|
0.9469
|
|
PASI75, n (%)
|
7/15 (46.7)
|
9/14 (64.2)
|
0.9469
|
|
Month 12
|
|
⊿TJC (M12-BL)
|
− 6 (− 8.5, − 3)
|
− 5 (− 11.5, − 2)
|
0.9175
|
|
⊿SJC (M12-BL)
|
− 4 (− 6, − 1.5)
|
− 5 (− 11.5, − 2)
|
0.4365
|
|
⊿DAPSA
|
− 18.4 (− 27.3, − 12.9)
|
− 19.45 (− 33.6, − 10.5)
|
0.8228
|
|
% decrease, DAPSA (M12)
|
− 87.4 (− 97.1, − 75.4)
|
− 72.0 (− 89.2, − 44.7)
|
0.0605
|
|
Proportion of REM, n (%)
|
10 (58.8)
|
4 (25.3)
|
*0.0399*
|
|
Proportion of REM/LDA, n (%)
|
15 (88.2)
|
13 (76.4)
|
0.3281
|
|
Minimal Disease Activity
|
14 (82.3)
|
7 (41.2)
|
*0.0162*
|
|
% improvement, PASI
|
92.7 (51.7, 100)
|
100 (72.7, 100)
|
0.3794
|
|
PASI90, n (%)
|
9/15 (60)
|
10/14 (71.4)
|
0.8502
|
|
PASI75, n (%)
|
9/15 (60)
|
11/14 (78.5)
|
0.9320
|
- Data are expressed as median (interquartile range [IQR] ) or number (%)
- TNF-i TNF inhibitors, IL-17-i IL-17 inhibitors, TJC tender joint counts 68, SJC swollen joint counts 66, DAPSA Disease Activity in Psoriatic Arthritis, LDA low disease activity, REM remission, PASI Psoriasis Area and Severity Index
- *p<0.05, by Mann-Whitney U test or chi-square test
